Zydus Lifesciences Receives USFDA Final Approval for Ascorbic Acid Injection with CGT Exclusivity
Zydus Lifesciences received final USFDA approval for Ascorbic Acid Injection USP, eligible for 180-day CGT exclusivity. The product is manufactured in Gujarat and will be marketed in the US. The brand product had annual sales of approximately USD 11.6 million (approx. ₹96.5 crore).
The approval of a generic drug with exclusivity is a positive step, but its impact is considered medium as it pertains to a specific therapeutic area and the sales figures of the reference drug are not exceptionally high.
The approval from the USFDA for a new drug, especially with competitive generic therapy exclusivity, is a positive development for the company's product pipeline and market presence.
Zydus Lifesciences Limited has announced the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP, 25,000 mg/50 mL (500 mg/mL), 5,000 mg/10 mL (500 mg/mL).
This injection is indicated for the short-term treatment of scurvy in adult and pediatric patients aged 5 months and older when oral administration is not feasible, insufficient, or contraindicated. The USFDA has designated this ANDA as a Competitive Generic Therapy (CGT), making it eligible for a 180-day exclusivity period starting from the first day of commercial marketing.
The manufacturing of Ascorbic Acid Injection will take place at Zydus' USFDA-approved injectable manufacturing facility located in Jarod, Gujarat. Zydus Pharmaceuticals (USA) Inc. will be responsible for marketing the product in the United States.
The reference listed drug (RLD) for this product, Ascor® Injection, reported annual sales of approximately USD 11.6 million (approximately ₹96.5 crore) in the US market as of June 2026. As of June 30, 2026, Zydus Lifesciences has secured 448 approvals and filed 513 ANDAs with the USFDA.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.